SecBot SecBot

EYPT

EyePoint, Inc.
Nasdaq· Laboratory Analytical Instruments· Inc. DE· CIK 0001314102 Industrials & Manufacturing
$0.3657 −0.03 (−8.57%)
Oct 26 4:00 PM ET · prev $0.4000
Market cap
$36.9M
Nano cap
Consensus
Buy
63% Buy or better · 19 analysts
Median target
$4.00
+994% · range $0.5000–31.00
Next earnings
Nov 4
in 9 days · EPS est. −$0.93
1 year
−97.0%
from $12.11 · Oct 27
30 days
−89.0%
from $3.31
52-week range
$0.3657–18.85
at the low
Avg volume 20D
17.10M
Oct 19 spike 184.37M
Short interest
🔒 Subscribers only
Insider net
−$81.3K
2 buyers · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read BEARISH 9 reports · 90 days
Balance 3 bearish · 0 bullish · 2 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 7/9 ·Next Earnings date, Nov 4, 2026
Strongest BEARISH EyePoint announced that its Phase 3 LUCIA trial of DURAVYU in wet AMD failed to meet its primary endpoint of…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders bought $72.0K at an average $5.95. 1 insider sold $153.3K. Price is 94% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 20 added (0 new), 13 trimmed or exited.

  • AnalystsBULLISH

    12 of 19 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.829 → −$0.932 over 90 days. 1 up, 9 down in 30 days.

  • TrendDOWNTREND

    90% below its 50-day average. New closing low $0.3657 on Oct 26.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 5.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ADAGE CAPITAL PARTNERS GP, L.L.C.ADD4,827,792$69.0M
BALYASNY ASSET MANAGEMENT L.P.ADD1,812,358$25.9M
AMERIPRISE FINANCIAL INCDOUBLED848,410$12.1M
DIMENSIONAL FUND ADVISORS LPDOUBLED841,746$12.0M
GOLDMAN SACHS GROUP INCTRIM465,087$6.7M
MORGAN STANLEYTRIM336,730$4.8M
Jump Financial, LLCADD320,757$4.6M
Woodline Partners LPDOUBLED300,463$4.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 63% rate it Buy or better
Strong Buy6Buy6Hold7Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +994%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 20, 2026Laidlaw & Co.
DOWNGRADE
DOWNGRADEHold
Oct 20, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Oct 20, 2026Guggenheim
DOWNGRADE
DOWNGRADENeutral
Oct 20, 2026JP Morgan
DOWNGRADE
DOWNGRADEUnderweight
Oct 20, 2026HC Wainwright & Co.
REITERATE
REITERATENeutral
Sep 2, 2026TD Cowen
DOWNGRADE
DOWNGRADEHold

Insider ledger

Form 4
$72.0K
bought · 2 insiders
$153.3K
sold · 1 insider
−93.9%
vs their $5.95 cost
DateInsiderTypeValue
Aug 20, 2026
Elston George
Chief Financial Officer
OTHER5,000 sh
Aug 20, 2026
Elston George
Chief Financial Officer
GIFT64,953 sh
Aug 18, 2026
Zaderej Karen L.
Director
BUY$52.3K
Jul 10, 2026
Duker Jay S.
President and CEO
EXERCISE16,667 sh
Jul 10, 2026
Duker Jay S.
President and CEO
TAX W/H$118.6K
Jun 30, 2026
Ribeiro Ramiro
Chief Medical Officer
EXERCISE$20.1K
Jun 30, 2026
Ribeiro Ramiro
Chief Medical Officer
SELL$36.6K
Jun 30, 2026
Ribeiro Ramiro
Chief Medical Officer
EXERCISE$20.1K

Earnings setup

Estimates
Nov 4
reports in 9 days
−$0.93
EPS estimate, this quarter
−12%
estimate change, 90 days
1↑ 9↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.93-$1.19–-$0.79-2.9%$233.1K
Next Q-$0.70-$1.11–-$0.36+13.4%$299.4K
Current FY-$3.62-$4.24–-$2.68+2.8%$1.7M
Next FY-$2.16-$4.14–-$0.84+21.7%$7.3M
Reddit
Recent posts
r/wallstreetbets Neutral 21d ago
$EYPT might save your marriage
1 upvotes · 0 comments
All social signals and their track records

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Oct 19, 2026Resumption ScheduledResumed
Aug 17, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
EyePoint announced that its Phase 3 LUCIA trial of DURAVYU in wet AMD failed to meet its primary endpoint of…
8-K — Impact 8/10
Oct 19, 2026 Trading halt
Halt Resumed: EYPT — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-19T10:55:00.000Z | Resumed 2026-10-19T11:40:00.000Z
Oct 19, 2026 SEC
EyePoint announced that LUCIA, the second pivotal Phase 3 trial of DURAVYU in wet AMD, failed to meet its primary…
8-K — Impact 7/10
Oct 19, 2026 Press
EyePoint announced that its second Phase 3 trial (LUCIA) of DURAVYU in wet AMD failed to meet the primary endpoint of…
Impact 7/10
Oct 7, 2026 SEC
Federated Hermes, Inc. filed an amendment to its Schedule 13G for EyePoint, Inc., disclosing beneficial ownership of…
SC 13G/A — Impact 3/10
Aug 20, 2026 Insider
Elston George disposed of 5,000 shares
Chief Financial Officer
Aug 20, 2026 Insider
Elston George gifted 64,953 shares
Chief Financial Officer
Aug 18, 2026 Insider
Zaderej Karen L. bought 10,600 shares
Director @ $4.93 ($52.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
EYPT Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Oct 19, 2026
Trading halt
Halt Resumed: EYPT — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-19T10:55:00.000Z | Resumed 2026-10-19T11:40:00.000Z
Oct 19, 2026
Press release
EyePoint Announces Strategic Prioritization
EyePoint Announces Strategic Prioritization...
Oct 19, 2026
FDA
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYUTM in Wet AMD ...
Oct 19, 2026
Trading halt
Trading Halt: EYPT — T1 (News Pending)
EyePoint, Inc. Common Stock | Market: NASDAQ | Code: T1 — News Pending
Oct 19, 2026
Trading halt
Trading Halt: EYPT — T3 (News and Resumption Times)
EyePoint, Inc. Common Stock | Market: NASDAQ | Code: T3 — News and Resumption Times

SecBot reports

13 filings · 4 press releases · 1 bullish · 2 bearish · 2 mixed · 8 neutral
All EYPT filing & press-release reports (17)